NasdaqGS:STOKBiotechs
Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting
Stoke Therapeutics (STOK) just gave investors another reason to pay attention, with fresh long term data on lead candidate zorevunersen showing sustained seizure reductions and cognitive gains in Dravet syndrome at the AES meeting.
See our latest analysis for Stoke Therapeutics.
That backdrop helps explain why, even after a small 1 day share price pullback, Stoke’s 30 day share price return of 13.62% and blistering year to date share price return of 191.57% signal powerful positive momentum...